USPatentGranted

ARF-P19, a novel regulator of the mammalian cell cycle

Granted 4 Apr 2000 · no office action yet

Application
129855
filed 6 Aug 1998
Publication
Not published
not published
Patent· this page
US 6,046,032
granted 4 Apr 2000

Life of the patent

3 dated events
⤢ drag to zoom19982000200220042006200820102012201420162018ProsecutionTerm & fees
ProsecutionTerm & feeshover for detail · click to open

Abstract

The INK4A (MTS1, CDKN2) gene encodes a specific inhibitor (InK4a-p16) of the cyclin D-dependent kinases CDK4 and CDK6. InK4a-p16 can block these kinase from phosphorylating the retinoblastoma protein (pRb), preventing exit from the G1 phase of the cell cycle. Deletions and mutations involving the gene encoding InK4a-p16, INK4A, occur frequently in cancer cells, implying that INK4a-p16, like pRb, suppresses tumor formulation. However, a completely unrelated protein (ARF-p19) arises in major part from an alternative reading frame of the mouse INK4A gene. Expression of an ARF-p19 cDNA (SEQ ID NO:1) in rodent fibroblasts induces both G1 and G2 phase arrest. Economical reutilization of protein coding sequences in this manner is without precedent in mammalian genomes, and the unitary inheritance of INK4a-p16 and ARF-p19 may reflect a dual requirement for both proteins in cell cycle control.

Claims

18 · 5 independent · depth 2
123456789101112131415161718
18 granted claims

Classifications

5 codes
USPC · US Patent Classification
435/69.1530/350514/44514/2514/12

Claim changes

Soon
Coming soonHow the claims changed between publication and grant

See which claims were amended, added or cancelled during examination, with every added and removed word marked.

AmendedAddedCancelledUnchanged

The published claims of this patent are not paired with the granted ones in what we hold.

File wrapper

Pendency
1.7 y
607 days filing → grant
Office actions
0
on the grant's record
Examiner
Karen Cochrane Carlson
art unit —
Citations: 138 back · 0 forward

Term & fees

See the term timeline — pendency span, in-force span, the maintenance fees paid and both computed expiry dates.

Log in to unlock

Validity challenges

See the validity challenges on record — reexaminations, IPRs and PGRs, with their institution decisions and outcomes.

Log in to unlock

Citations

See every patent this one cites and every patent that cites it back — publication, assignee, and how each one was found.

Log in to unlock